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HIF-1(HIF-1) is a major transcription factor regulating the response of tumor cells to
hypoxia and is comprised of HIF-1α and Arnt (HIF-1β). In mammalian cells, HIF-1 protein levels are
regulated by three HIF-prolyl hydroxylases, termed PHD1, PHD2 and PHD3. To assess whether intracellular
localization of PHD1 and PHD2 affects the hypoxic response via HIF-1, we investigated the localization signal
of PHDs. PHD1 possessed at least one nuclear localization signal (NLS), and PHD2 contained a region as
essential for nuclear export in their N-terminal region. Treatment of cells with leptomycin B revealed that
PHD2 was able to shuttle between the cytoplasm and the nucleus. Reporter assay indicated that differences
in the intracellular distribution of PHD1 did not inﬂuence on HIF-1α activity. However, a PHD2 mutant
lacking the region for nuclear export exhibited signiﬁcantly reduced effect to HIF-1α activity compared to
wild-type PHD2, suggesting that the regulation of the intracellular distribution of PHD2 is an effective
pathway for the control of the hypoxic response.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionHypoxia-inducible factors (HIFs) are the transcriptional regulators
that play essential roles in the hypoxic response [1,2]. HIFs bind to
hypoxia response element (HRE), located in the regulatory region of
the target genes such as erythropoietin and vascular endothelial
growth factor. HIFs are heterodimers formed by two subunits, the
hypoxia-inducible factor-α (HIFα) and the constitutively expressed
Arnt (HIF-1β) [3]. There are three HIFα proteins, HIF-1α, HLF (HIF-
2α) and HIF-3α, reported previously [3–5]. Both HIF-1α and HLF
translocate to the nucleus following stabilization in response to
hypoxia, and ﬁnally form heterodimers (called as HIF-1 and HIF-2,
respectively) with Arnt [6]. Thus, both HIF-1 and HIF-2 activate trans-
cription of target genes bearing HRE in response to hypoxia.
In normoxia, rapid degradation of HIF-1α is mediated by the
ubiquitin-dependent pathway [7]. The tumor suppressor von Hippel-
Lindau gene product (pVHL) is involved in the proteasomal degrada-
tion of HIF-1α [8]. Furthermore, it was reported that hydroxylation of
speciﬁc prolines in the oxygen-dependent degradation (ODD) domain
of HIF-1α is required for the recognition of pVHL [9–11]. Subsequent
studies revealed a family of three prolyl 4-hydroxylase-domain
containing proteins (PHDs) 1, 2 and 3 as HIF-1α prolyl hydroxylases
[12,13]. In hypoxia, decrease in hydroxylase activity of PHDs due to the
short supply of oxygen results in the accumulation of HIF-1α and the
induction of target gene expression controlled by HRE. Thus, PHDs are
regarded as a cellular oxygen sensor.
Many studies have revealed functional differences among PHD1,
PHD2 and PHD3 [14–16]. These three enzymes share the catalyticasumoto).
ll rights reserved.domain with sequence similarities and conserve amino acids for
coordination to Fe (II) ion. Furthermore, Km values of these PHDs for
O2 are comparable [14]. However, PHD2 has been shown to play a
crucial role in the rapid degradation of HIF-1α in normoxia [17].
Conservation of the catalytic domain and similarity of the enzymatic
activity between PHD1 and PHD2 suggest that the diversed N-
terminal region is essential for their particular functions. It has been
reported that PHD1 is present exclusively in the nucleus, while PHD2
is located mainly in the cytoplasm [18]. Thus, it would be possible that
the localization gives rise to the functional diversity of these proteins.
To evaluate whether the intracellular localization of PHD1 and PHD2
affects HIF-1α activity, we determined the localization signal in PHD1
and PHD2. Subsequently, we examined the effect of the intracellular
localization of PHD1 and PHD2 on their activity.
2. Materials and methods
2.1. Cell culture and DNA transfection
COS-7 and Hep3B cells were obtained from Cell Resource Center for
Biomedical Research (Institute of Development, Aging and Cancer,
Tohoku University, Japan). COS-7, Hep3B and HEK293T cells were
maintained in Dulbecco's modiﬁed Eagle's medium supplementedwith
10% fetal bovine serum. DNA transfection into Hep3B cells in a 60 mm
dishwas carriedout by the calciumphosphatemethod asdescribed [19].
2.2. Fluorescence observation of cultured cells
COS-7 cells grown on the cover glass were transfected with 0.5 μg
of plasmids expressing PHD variants fused to Citrine [20] using
FuGENE6 transfection reagent (Roche), and incubated for 40 h before
793K. Yasumoto et al. / Biochimica et Biophysica Acta 1793 (2009) 792–797ﬁxation in 4% paraformaldehyde in PBS. The ﬁxed cells were incubated
in 0.2 μg/ml of DAPI (4′,6′-diamidino-2-phenylindole) for 5 min.
Imaging was performed with an Olympus BX50 ﬂuorescence micro-
scope and the Olympus DP70 digital camera. The ﬂuorescent color of
DAPI was changed from blue to red on a computer.
2.3. Construction of plasmids
A full-length PHD1 cDNA was subcloned into pBOS vector [21].
PHD1 was ampliﬁed by PCR and the fragment was inserted into
HindIII/BamHI site of Citrine-C1 (pEYFP-C1 (Q69M), Clontech).
Chimeric plasmids for Citrine-PHD1 deletion mutants were con-
structed as follows. A DNA fragment containing the partial region of
PHD1 was ampliﬁed by PCR using appropriate primers and inserted
into the HindIII/BamHI sites of Citrine-C1.
Mutant plasmids, Citrine-PHD1(K102A), Citrine-PHD1(R106A),
Citrine-PHD1(R113A), Citrine-PHD1(R119A), Citrine-PHD1(R134A)
with mutations in the NLS were constructed using QuikChange II
site-directed mutagenesis kit (Stratagene).
A full-length PHD2 cDNA was subcloned into the EcoRV site of
pBluescriptIISK+ vector (Stratagene) termed as pBS-hPHD2. PHD2
was excised with BamHI/HindIII and ligated into BglII/HindIII site of
Citrine-C1, termed as Citrine-PHD2(1–426). A series of Citrine-PHD2
deletion mutants was constructed by the digestion of Citrine-PHD2
(1–426) with suitable restriction enzymes. All DNA constructions
were validated by sequence analysis.
2.4. pVHL-HIF-1α binding assay
pVHL-HIF-1α binding assay was performed as described pre-
viously [19]. Cell extracts were prepared from HEK293T cellsFig. 1. Determination of the nuclear localization signal (NLS) for human PHD1. (A) Wild-type
the deletions were shown. Dark box represents the catalytic domain of PHD1. Each chimeric p
and their merged images were shown on the right. Scale bars represent 20 μm. (B) Mutation
protein was shown at the top. Basic amino acids are underlined and 5 basic amino acids in t
Citrine and DAPI and merged images were shown below.transiently transfected with the FLAG-tagged PHD expression
plasmid. Samples were analyzed by SDS-PAGE and radioactivities
were quantitated with BAS-1000 bioimaging system (Fujiﬁlm Corp.,
Tokyo).
3. Results
3.1. PHD1 contains a nuclear localization signal
To investigate the intracellular localization of PHD1 and PHD2,
Citrine (improved equivalent of EYFP)-fused PHD1 or PHD2 was
expressed in COS-7 cells and observed the distribution with the
ﬂuorescent microscopy. The subcellular localization of Citrine-PHD1
or Citrine-PHD2 with the ﬂuorescent microscopy was comparable to
FLAG-tagged PHD1 or FLAG-tagged PHD2 with immunocytochemical
detection, respectively (data not shown). The intracellular distribu-
tion of PHD1 and PHD2 is consistent with the previous results [18].
Subsequently we examined the intracellular localization of various
deletion mutants of PHD1 fused with Citrine expressed in COS-7 cells
to search the nuclear localization signal (NLS) (Fig. 1A). C-terminal
region of PHD1 did not confer nuclear accumulation. Deletions in the
N-terminal region showed that the region from amino acids 89 to 134
is sufﬁcient for the NLS activity (Fig. 1A). However, the two divided
regions, amino acids 89–112 and 113–134, were insufﬁcient for the
NLS. Therefore, we focused the role of basic amino acids in the region
89 to 134. Five basic amino acids selected from 89–134 were
substituted by alanine (Fig. 1B). Four mutants (K102A, R106A,
R113A, and R134A) were still localized in the nucleus. However,
R119A mutant was distributed both in the nucleus and the cytoplasm
indicating that the arginine 119 is important for the nuclear
localization of PHD1. The NLS usually contains a cluster of basicand various deletion mutants of human PHD1 were fused with Citrine, and positions of
roteinwas transiently expressed in COS-7 cells. Images of Citrine and DAPI ﬂuorescence
al analysis of the NLS of human PHD1. Amino acid sequence from 89–134 of the PHD1
he sequence were substituted with alanine, respectively. Images of the ﬂuorescence of
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positions 118–120) is an essential component of the NLS for PHD1.
3.2. PHD2 contains a nuclear exclusion signal
We then investigated the functional region for intracellular
distribution in the PHD2 sequence. Wild type PHD2 is mainly located
in the cytoplasm as shown in Fig. 2A and this result is consistent with
the previous result [18]. Experiments using deletion mutants from C-
terminus of PHD2 revealed that the catalytic domain of PHD2 did not
affect the distribution. Further deletion of the region between 123 and
196 diminishes the cytoplasmic localization of the ﬂuorescent protein
suggesting that the region between 123 and 196 could contain a
nuclear exclusion signal (NES). However, an internal deletion mutant
(Δ116–196) was localized exclusively in the cytoplasm (Fig. 2B)
suggesting that the region between 116 and 196 is not important for
the cytoplasmic localization of PHD2. Together with the fact that the
catalytic domain of PHD2 has no effect on the intracellular distribu-
tion, it is likely that the N-terminal region (1–123) may include the
region as essential for nuclear export. The distribution of Citrine-PHD2
(1–123) in both the cytoplasm and the nucleusmay be due to its small
size. Deletion experiments using mutants from N-terminus of PHD2
showed that a short 5 residues deletion to the N-terminal was no
effect on the distribution. However, deletion of the N-terminal 20Fig. 2. Determination of the nuclear exclusion signal (NES) for PHD2. (A) Structure of wild-t
shown on the left. Dark box represents the catalytic domain of PHD2. Each chimeric protein
merged images were represented on the right. Scale bars represent 20 μm. (B) Structure of th
the putative NES described in the manuscript. About 300 cells were observed and classiﬁedresidues caused translocation of PHD2 into the nucleus (Fig. 2A).
These results strongly suggest that the region 6–20 is involved in the
nuclear export of PHD2 and could be regarded as a region as essential
for nuclear export.
There is a putative NES from 188 to 195 in PHD2 using the
computational prediction [22]. To determine the role of the putative
NES, we constructed several internal deletion mutants and subjected
to the analysis. Deletion mutants that lack the segment of amino acids
188–195 showed no signiﬁcant increase of the accumulation in the
nucleus compared with the wild type PHD2 (Fig. 2B).
3.3. PHD2 protein shuttles between cytoplasm and nucleus
The presence of the region as essential for nuclear export in the
PHD2 protein prompted us to assess the possibility of PHD2 shuttling
between cytoplasm and nucleus. Therefore, we treated the cells with
leptomycin B (LMB) and observed changes in the intracellular
distribution of PHD2 (Fig. 3A). Treatment of cells with LMB promoted
nuclear accumulation of the PHD2 in a time-dependent manner. LMB
speciﬁcally inhibits nuclear exporting function of CRM1 [23]. These
results, therefore, represent the nucleocytoplasmic shuttling of PHD2.
Furthermore, we analyzed a role of CRM1 in the nuclear exclusion of
PHD2 (Fig. 3B). Co-expression of CRM1 did not affect the intracellular
distribution of Citrine-PHD2 compared with Citrine-PHD2 alone. Inype and mutants deleted from C-terminus and N-terminus of PHD2 fused to Citrine was
was transiently expressed in COS-7 cells. Images of Citrine and DAPI ﬂuorescence and
e internally deleted PHD2 fused to Citrine was shown on the left. Closed box represents
for the intracellular localization as indicated on the right.
Fig. 3. Translocation of PHD2 into the nucleus. (A) Citrine was fused with full-length
PHD2 and expressed in COS-7 cells. Cells were treated with 20 nM leptomycin B (LMB)
and images of Citrine and DAPI ﬂuorescence and merged images were shown on the
right. The alteration of PHD2 subcellular localizationwas dependent on the time of LMB
treatment as shown on the left. About 300 cells were observed and compiled for the
intracellular localization. (B) Shuttling of the PHD2 relies on the function of CRM1.
Citrine-PHD2 was co-expressed with CRM1 or CRM1 (C528S) in COS-7 cells followed by
the treatment with or without LMB for 4 h. Scale bars represent 40 μm.
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signiﬁcantly restored the cytoplasmic localization of PHD2 in the
presence of LMB. These results indicate that the nuclear exclusion of
PHD2 requires functional CRM1.
3.4. Functional relevance of the intracellular localization and the
enzymatic activity of PHD1 and PHD2
In order to investigate the role of the nuclear accumulation of
PHD1 in the enzymatic activity, we compared the prolyl hydroxylase
activity between wild type and the R119A mutant. Both were
expressed in HEK293T cells, and subjected to in vitro pVHL-HIF-1α
binding assay to measure HIF prolyl hydroxylase activity [19,25]. The
expression level of wild-type and R119Amutant was nearly equivalent
as examined bywestern blotting (Fig. 4A). Results of the binding assay
clearly indicated that the prolyl hydroxylase activity of R119A mutant
was comparable to that of wild type (Fig. 4B). Next, we evaluated the
effect of the location of PHD1 on the transcriptional activity of HIF-1α
using reporter assay in Hep3B cells (Fig. 4C). The proline hydroxylase
activity was represented as a reduction of the reporter activity by
expressed wild type PHD1 or the R119A mutant. Both wild-type PHD1
and the R119A mutant reduced the transcriptional activity of HIF-1α
in a dose-dependent manner, and the ratio of the reduction seems to
be nearly the same, suggesting that wild-type and R119A mutant have
equivalent activity for the HIF-1α degradation despite differences in
the intracellular localization.We investigated whether different intracellular distribution of
PHD2 inﬂuences its prolyl hydroxylase activity and transactivation
activity of HIF-1α. Wild type PHD2 and an N-terminal deletion
mutant, PHD2(20–426), were expressed to subject to pVHL-HIF-1α
binding assay.We conﬁrmed that the expression level of wild type and
the mutant shows no signiﬁcant differences (Fig. 4D). Relative prolyl
hydroxylase activities of bothwild type and the deletionmutant PHD2
were comparable to each other (Fig. 4E). Furthermore, reporter assay
was performed to evaluate the prolyl hydroxylase activity of wild type
and the deletion mutant toward HIF-1α of PHD2 in Hep3B cells. As
shown in Fig. 4F, the reporter activity was signiﬁcantly decreased
when a lower dose of the expression plasmid for wild-type was used
for transfection. However, transfection with the same dose of the
mutant plasmid did not cause reduction of reporter activity. At higher
dose of transfection, the expressed mutant also showed reduction of
the activity, but the remaining reporter activity was still weakly higher
than that resulted from transfection of wild-type. These results
revealed that the different localization of PHD2 affects the stability of
HIF-1α.
4. Discussion
In this report, we identiﬁed a functional NLS in the N-terminal
region of PHD1. Typical NLS is classiﬁed into two groups, a single basic
type and a bipartite basic type, according to the location of basic
amino acids [26]. A basic amino acid cluster KRK (at positions
118–120) was noticeable in the NLS sequence of PHD1. However, the
cluster was insufﬁcient to constitute a complete NLS because the
portion of amino acids 113–134 that contains the KRK cluster was not
enough to accumulate Citrine in the nucleus (Fig. 1B). The portion of
amino acids 89–134 was sufﬁcient to function as an NLS suggesting
that the NLS of PHD1 is a bipartite type and critical amino acids
are encompassed between the portion of amino acids 89–112 and
113–134.
Recently, Berchner-Pfannschmidt et al. have revealed that the
endogenous PHD2 is accumulated dominantly in the nucleus using
several cells [27]. Several reports have described the intracellular
distribution of PHD2 previously. Forcedly expressed PHD2 fused to the
ﬂuorescent protein or an epitope tag predominantly localized in the
cytoplasm [18,28, and our data]. The subcellular localization of PHD2-
EGFP was comparable to that of endogenous PHD2 in several HNSCC-
derived cell lines [29] suggesting that the intracellular localization of
PHD2 depends on the cell type. Although HA-tagged PHD2 was
detected mainly in the cytoplasm of HeLa cells [28], both extracts
prepared from the cytoplasm and the nuclei of HeLa cells contained
endogenous PHD2 [30]. Thus, the discrepancy of the intracellular
localization of PHD2 is possibly caused by the cell type or the
detection method used in each study.
Endogenous PHD1 was present in a monomeric state in cultured
cells and the state was not altered in both normoxic and hypoxic
conditions [31]. In contrast, PHD2 forms a high molecular mass
complex [31,32]. Several reports described about factors that associate
with PHD2 and regulate prolyl hydroxylase activity of PHD2
[28,30,33]. FRAP experiments using UT-SCC2 cells indicated that the
complex formation of PHD2 is different between the cytoplasmic and
the nuclear PHD2 [29]. Interestingly, PHD2 was relocalized from the
cytoplasm into the nucleus in head and neck squamous cell
carcinomas (HNSCCs), and the ratio of nuclear localization of PHD2
was correlated with the histologic grade of the tumors [29]. In a subset
of the aggressive tumor cells, concomitant high HIF-1α expression
was also observed, implying that elevated PHD2 levels are not
sufﬁcient to down-regulate HIF-1α. Moreover, the ubiquitination
assay using oxygen-dependent degradation domain of HIF-1α as a
substrate demonstrated that the ubiquitination activity of the
cytoplasmic extract from human renal clear carcinoma cells (RCC4)
was much higher than that of the nuclear extract [25]. This result
Fig. 4. Comparison of the prolyl hydroxylase activity between wild-type and mutated PHD1 and PHD2. (A) and (D) FLAG-tagged PHDs were expressed in HEK293T cells. Whole cell
extracts were prepared from transfected cells andwere compared for the expression levels bywestern blotting.Wild type andmutant R119A PHD1were compared (A), and wild type
and the N-terminal deletion mutant (20–426) PHD2 were compared (D). (B) and (E) Cell extracts were subjected to pVHL-HIF-1α binding assay. Radioactive image is shown at the
top, and quantitated data is graphically shown below. Comparison of wild type and mutant PHD1 or PHD2 is represented on (B) and (E), respectively. (C) and (F) Reporter assay for
evaluation of the prolyl hydroxylase activity of wild-type and mutant PHDs. Reporter plasmid HRE4SV40Luc was transfected with or without the effector plasmid pBOS-HIF-1α in
Hep3B cells. The prolyl hydroxylase activity of each PHD1 (C) or PHD2 (F) was represented by the reduction of the reporter activity. ⁎, signiﬁcant statistical difference (pb0.05).
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dominant in RCC4 cells. Our result demonstrated that the reduced
cytoplasmic localization of PHD2 resulted in the decreased enzymatic
activity (Fig. 4F). These results indicate that the PHD2 complex formed
in the cytoplasm has higher prolyl hydroxylase activity than that in
the nucleus. On the other hand, recent study has demonstrated that
PHD activity of the nuclear extract is signiﬁcantly higher than that of
the cytoplasmic extract using human osteosarcoma cells (U-2OS) [27].
We presume that the differences of the cell type used in their
experiments account for the distinct result about PHD activity in the
cytoplasm and the nucleus. Although PHD2 forms multi-protein
complexes both in the cytoplasm and the nucleus, it is likely that those
complexes may be sensitive to the extraction procedure for in vitro
PHD assay. Further detailed analysis about the complex of PHD2 is
required in the future.
We identiﬁed a segment of amino acids 6–20 of PHD2 as the region
as essential for nuclear export and the export of PHD2 from the
nucleus was dependent upon CRM1. Previous studies indicated that
the export substrates of CRM1 contain a short leucine-richmotif as the
NES [34]. However, there is no leucine residue in the segment of
amino acids 6–20 of PHD2, suggesting that the segment mayrepresent a novel type of NES. Although the portion was required
for the function as the NES, we could not detect direct interaction
between PHD2 and CRM1 by immunoprecipitation (data not shown)
possibly because of the low afﬁnity of the NES substrates to the CRM1-
RanGTP complex [34]. The alternate possibility cannot be excluded
that the portion of amino acids 6–20 functions to interact with an
additional protein factor that facilitates translocation of PHD2 into the
cytoplasm. Further investigation to clarify these points is required for
detailed characterization of the segment of amino acids 6–20 of PHD2.
Moreover, import signals to the nucleus are necessary for nucleocy-
toplasmic shuttling of PHD2. Dupuy et al. predicted that PHD2 has two
putative NLSs (located in 51–54, and 98–114) [35]. Characterization of
the NLSs in the N-terminal region of PHD2 should be addressed.
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